Summary
In this study the effects of SN-38 on colon adenocarcinoma cell lines expressing wild-type p53 (LS174T) or mutant non-functional p53 (HT29) have been investigated. On exposure to SN-38, HT29 cells rapidly progressed through G1 and S and arrested in G2/M. Release and concomitant increase in apoptosis after 48 h was concentration- and time-dependent (P < 0.001), being more rapid at higher concentrations, but reaching plateau at 10 ng ml–1 with prolonged exposure. LS174T cells showed only a small increase in apoptosis, and only at high concentrations (50–100 ng ml–1). The main effect of SN-38 in LS174T cells was prolonged cell cycle arrest, which was independent of concentration. Arrest occurred in all phases of the cell cycle, with the distribution depending on concentration (P < 0.001) and not duration (P > 0.05). With increasing concentration, LS174T cells arrested in G2/M, S and G1. Cell cycle arrest was coincident with increased p53 expression in each phase of the cell cycle. Expression in G1 increased with time and concentration (P < 0.001, P = 0.01 respectively), whereas in S and G2/M p53 expression increased only with time (P < 0.001). Dose-dependent p53-associated G1 arrest, in the absence of DNA synthesis indicates an additional cytotoxic mechanism for SN-38, which requires higher concentrations than the S phase mechanism, and detection of which seems to involve p53. For incubations with the same ED (exposure × duration), apoptosis in HT29 cells was significantly higher for prolonged exposure to lower concentrations, whereas in LS174T cells there was a trend towards increased apoptosis with shorter exposures to higher concentrations, indicating a schedule effect of SN-38. Although expression of wild-type p53 leads to a more rapid induction of apoptosis, SN-38 cytotoxicity was generally greater in cells with mutant p53, as wild-type cells escaped apoptosis by p53 associated prolonged cell cycle arrest. Thus, pulsed schedules with higher doses may be more effective in cells expressing wild-type p53, whereas continued exposure with protracted schedules may be more active in cells expressing mutant p53.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Armand, JP (1996). CPT-11: clinical experience in phase I studies. Semin Oncol 23: 27–33.
Bendixen, C, Thomsen, B, Alsner, J & Westergaard, O (1990). Camptothecin-stabilized topoisomerase I–DNA adducts cause premature termination of transcription. Biochemistry 29: 5613–5619.
Bissery, MC, Vrignaud, P, Lavelle, F & Chabot, GG (1996). Experimental antitumour activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7: 437–460.
Burris, HAd, Hanauske, AR, Johnson, RK, Marshall, MH, Kuhn, JG, Hilsenbeck, SG & Von Hoff, DD (1992). Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84: 1816–1820.
Canal, P, Gay, C, Dezeuze, A, Douillard, JY, Bugat, R, Brunet, R, Adenis, A, Herait, P, Lokiec, F & Mathieu-Boue, A (1996). Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14: 2688–2695.
Carmichael, J, DeGraff, WG, Gazdar, AF, Minna, JD & Mitchell, JB (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47: 943–946.
Catimel, G, Chabot, GG, Guastalla, JP, Dumortier, A, Cote, C, Engel, C, Gouyette, A, Mathieu-Boue, A, Mahjoubi, M & Clavel, M (1995). Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors [see comments]. Ann Oncol 6: 133–140.
Darzynkiewicz, Z, Li, X & Gong, J (1994). Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol 41: 15–38.
Del Bino, G, Skierski, JS & Darzynkiewicz, Z (1990). Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res 50: 5746–5750.
Di Leonardo, A, Linke, SP, Clarkin, K & Wahl, GM (1994). DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540–2551.
Dubrez, L, Goldwasser, F, Genne, P, Pommier, Y & Solary, E (1995). The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9: 1013–1024.
Fukuoka, M & Masuda, N (1994). Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 34: S105–S111.
Goldwasser, F, Shimizu, T, Jackman, J, Hoki, Y, O'Connor, PM, Kohn, KW & Pommier, Y (1996). Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56: 4430–4437.
Hochster, H, Liebes, L, Speyer, J, Sorich, J, Taubes, B, Oratz, R, Wernz, J, Chachoua, A, Raphael, B & Vinci, RZ et al (1994). Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12: 553–559.
Horiguchi, T, Hayashi, K, Tsubotani, S, Iinuma, S, Harada, S & Tanida, S (1994). New naphthacenecarboxamide antibiotics, TAN-1518 A and B, have inhibitory activity against mammalian DNA topoisomerase I. J Antibiotics 47: 545–556.
Houghton, PJ, Cheshire, PJ, Hallman, JDn, Lutz, L, Friedman, HS, Danks, MK & Houghton, JA (1995). Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393–403.
Hsiang, YH & Liu, LF (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722–1726.
Hsiang, YH, Hertzberg, R, Hecht, S & Liu, LF (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873–14878.
Hsiang, YH, Lihou, MG & Liu, LF (1989). Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082.
Kawato, Y, Furuta, T, Aonuma, M, Yasuoka, M, Yokokura, T & Matsumoto, K (1991). Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192–198.
Liu, LF (1989). DNA topoisomerase poisons as antitumor drugs. [Review]. Annu Rev Biochem 58: 351–375.
Muggia, FM, Creaven, PJ, Hansen, HH, Cohen, MH & Selawry, OS (1972). Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemotherapy Reports – Part 1 56: 515–521.
Nelson, WG & Kastan, MB (1994). DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815–1823.
Pantazis, P, Mendoza, JT, Early, JA, Kozielski, AJ, Natelson, EA & Giovanella, BC (1993). 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur J Haematol 50: 81–89.
Phillips, PC, Janss, A & Kaufmann, SH (1994). Topoisomerase I inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumors cell lines. Proc Annu Meet Am Assoc Cancer Res 35.
Poot, M, Hiller, K, Heimpel, S & Hoehn, H (1995). Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity. Exp Cell Res 218: 326–330.
Rolley, N, Butcher, S & Milner, J (1995). Specific DNA binding by different classes of human p53 mutants. Oncogene 11: 763–770.
Rubin, E, Pantazis, P, Bharti, A, Toppmeyer, D, Giovanella, B & Kufe, D (1994). Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem 269: 2433–2439.
Slichenmyer, WJ, Rowinsky, EK, Grochow, LB, Kaufman, SH & Donehauwer, RC (1994). Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34: S53–S57.
Solary, E, Dubrez, L, Eymin, B, Bertrand, R & Pommier, Y (1996). [Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors]. Bull Cancer (Paris) 83: 205–212.
Von Hoff, D, Burris, HR, Eckardt, J, Rothenberg, M, Fields, SM, Chen, SF & Kuhn, JG (1994). Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol,
Wang, JC (1985). DNA topoisomerases. Annu Rev Biochem 54: 665–697.
Author information
Authors and Affiliations
Additional information
Current address:Signal Transduction & Molecular Pharmacology Team, CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, E block, Sutton, Surrey SM2 5NE, UK
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Poele, R., Joel, S. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br J Cancer 81, 1285–1293 (1999). https://doi.org/10.1038/sj.bjc.6694370
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6694370
Keywords
This article is cited by
-
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
Investigational New Drugs (2013)
-
Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model
Cancer Chemotherapy and Pharmacology (2007)
-
Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth
Oncogene (2006)
-
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175
Cancer Chemotherapy and Pharmacology (2005)
-
Adenovirus-mediated gene transfer of P16INK4/CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo
Cancer Gene Therapy (2002)